6311-52-0

Basic information

• Product Name: 3,6-DIMETHYL-2,4-DINITROANILINE
• Synonyms: 3,6-DIMETHYL-2,4-DINITROANILINE
• CAS NO: 6311-52-0
• Molecular Formula: C₈H₉N₃O₄
• Molecular Weight: 211.17
• Mol File: 6311-52-0.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 403.8 °C at 760 mmHg
• Flash Point: 198 °C
• Appearance: /
• Density: 1.427 g/cm³
• Vapor Pressure: 9.92E-07mmHg at 25°C
• Refractive Index: 1.638
• CAS DataBase Reference: 3,6-DIMETHYL-2,4-DINITROANILINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3,6-DIMETHYL-2,4-DINITROANILINE(6311-52-0)
• EPA Substance Registry System: 3,6-DIMETHYL-2,4-DINITROANILINE(6311-52-0)

Safety Data

• Hazardous Substances Data: 6311-52-0(Hazardous Substances Data)

Usage

General Description

3,6-DIMETHYL-2,4-DINITROANILINE, also known as MNA, is a yellow crystalline compound that is primarily used as a precursor in the manufacturing of dyes, pigments, and pharmaceuticals. It is classified as a hazardous substance due to its potential to cause skin and eye irritation, and is considered an environmental pollutant. MNA is also used in the manufacturing of explosives, making it a controlled substance under various international treaties and regulations. Its chemical structure consists of a benzene ring with two methyl and two nitro groups, and its high level of reactivity and explosive potential make it a substance that requires careful handling and storage.

InChI:InChI=1/C8H9N3O4/c1-4-3-6(10(12)13)5(2)8(7(4)9)11(14)15/h3H,9H2,1-2H3

Upstream product

• 2050-44-4 N-(2,5-dimethylphenyl)acetamide 
• 77806-32-7 bromo-2 dinitro-3,5 p-xylene 
• 7664-41-7 ammonia 
• 602-27-7 2,3,5-trinitro-p-xylene 
• 108-95-2 phenol 

Downstream Products

• 71491-47-9 1-chloro-2,5-dimethyl-4,6-dinitrobenzene 
• 101935-22-2 3,6-dimethyl-4-nitro-o-phenylenediamine 
• 609-92-7 2,5-dimethyl-1,3-dinitrobenzene 
• 170918-29-3 4,7-dimethyl-5-nitro-1⁽³⁾H-benzimidazole 

Relevant articles and documents

2-IMIDAZOLINE, 2-OXAZOLINE, 2-THIAZOLINE, AND 4-IMIDAZOLE DERIVATIVES OF METHYLPHENYL, METHOXYPHENYL, AND AMINOPHENYL ALKYLSULFONAMIDES AND UREAS AND THEIR USE

The present invention concerns novel compounds represented by the Formula: STR1 wherein: A is R 1 q (R 3 R 60 N). sub.m (Z)(NR 2) n ; m and q are each 0 or 1, with the proviso that when q is 1, m is 0 and when q is 0, m is 1; Z is C=O or SO 2 ; n is 1 with the proviso that, when Z is C=O, m is 1; X is--NH--,--CH 2--, or--OCH 2--; Y is 2-imidazoline, 2-oxazoline, 2-thiazoline, or 4-imidazole; R 1 is H, lower alkyl, or phenyl, with the proviso that, when R 1 is H, m is 1; R 2, R 3, R 60 are each independently H, lower alkyl, or phenyl; R 4, R 5, R. sup.6, and R 7 are each independently hydrogen, lower alkyl,--CF. sub.3, lower alkoxy, halogen, phenyl, lower alkeny, hydroxyl, lower alkylsulfonamido, or lower cycloalkyl, wherein R. sup.2 and R 7 optionally may be taken together to form alkylene or alkenylene of 2 to 3 atoms in an unsubstituted or optionally substituted 5-or 6-membered ring, wherein the optional substituents on the ring are halo, lower alkyl, or--CN, with the proviso that, when R 7 is hydroxyl or lower alkylsulfonamido, then X is not--NH--when Y is 2-imidazoline. The compounds include pharmaceutically acceptable salts of the above. In the above formula A may be, for example, (R 1 SO 2 NR 2--), (R. sup.3 R 60 NSO 2 NR 2--), or (R 3 R 60 NCONR 2--). The invention also includes the use of the above compounds, and compositions containing them, as alpha 1A/1L agonists in the treatment of various disease states such as urinary incontinence, nasal congestion, priapism, depression, anxiety, dementia, senility, Alzheimer's, deficiencies in attentiveness and cognition, and eating disorders such as obesity, bulimia, and anorexia.